EMA Application withdrawn: Luxceptar — Kiadis Pharma Netherlands B.V.

View source ↗

Summary

EMA status shows that the Luxceptar application has been withdrawn by the applicant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Vs Host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Luxceptar

Snippet

Status: Application withdrawn. Therapeutic area: Graft vs Host Disease;Hematopoietic Stem Cell Transplantation. MAH: Kiadis Pharma Netherlands B.V.. Orphan medicine